Drug reference

Basiliximab

Monoclonal Antibody · Immunosuppressant

Monoclonal AntibodyImmunosuppressant

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

Manufacturer advises avoid—no information available.

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist, preventing T-lymphocyte proliferation. It targets the CD25 subunit of the interleukin-2 receptor (IL-2R) on T-cells, thereby limiting clonal expansion and promoting immune tolerance.

Indications

Prophylaxis of acute rejection in allogeneic renal transplantation (used in combination with ciclosporin and corticosteroid-containing immunosuppression regimens)Prophylaxis of graft rejection in cardiac transplantation (off-label, increased risk of serious cardiac side-effects)prophylaxis of acute organ transplant rejectioninduction therapy in solid-organ transplantation

Dosing

Adult: Initially 20 mg, administered within 2 hours before transplant surgery, followed by 20 mg after 4 days. Dose to be administered after surgery. Withhold second dose if severe hypersensitivity or graft loss occurs. Administered by intravenous injection or intravenous infusion.

Pharmacokinetics

Half-life

7 days

Contraindications

Severe hypersensitivity (subsequent doses)

Side effects

Common

AnaemiaConstipationDiarrhoeaDyspnoeaElectrolyte imbalanceHeadacheHypercholesterolaemiaHypertensionHypotensionNauseaPainPeripheral oedemaRespiratory disordersSkin reactionsSneezingTachycardiaWeight increasedgood safety profile

Serious

Capillary leak syndrome
Cytokine release syndrome
Heart failure
Myocardial infarction
Pulmonary oedema
Severe hypersensitivity
Increased risk of infection (particularly due to tissue-invasive cytomegalovirus)
Blood disorders (e.g. leucopenia)
Post procedural wound complication
anaphylactic reactions
rare lymphoproliferative disorders
opportunistic infections
beta adrenergic blocking effects (worsening of heart failure and bronchospasm)